Targeting the Wnt/β-catenin signaling pathway in cancer
| Autor: | Xin Wang, Ya Zhang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research Wnt/β-catenin signaling pathway medicine.medical_treatment Antineoplastic Agents Review medicine.disease_cause lcsh:RC254-282 Targeted therapy 03 medical and health sciences 0302 clinical medicine Cancer stem cell Neoplasms medicine Animals Humans Molecular Targeted Therapy Receptor Molecular Biology Wnt Signaling Pathway beta Catenin Cancer Cell growth business.industry lcsh:RC633-647.5 Wnt signaling pathway Hematology lcsh:Diseases of the blood and blood-forming organs medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Wnt Proteins 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research Neoplastic Stem Cells Signal transduction Carcinogenesis business |
| Zdroj: | Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-16 (2020) Journal of Hematology & Oncology |
| ISSN: | 1756-8722 |
| Popis: | The aberrant Wnt/β-catenin signaling pathway facilitates cancer stem cell renewal, cell proliferation and differentiation, thus exerting crucial roles in tumorigenesis and therapy response. Accumulated investigations highlight the therapeutic potential of agents targeting Wnt/β-catenin signaling in cancer. Wnt ligand/ receptor interface, β-catenin destruction complex and TCF/β-catenin transcription complex are key components of the cascade and have been targeted with interventions in preclinical and clinical evaluations. This scoping review aims at outlining the latest progress on the current approaches and perspectives of Wnt/β-catenin signaling pathway targeted therapy in various cancer types. Better understanding of the updates on the inhibitors, antagonists and activators of Wnt/β-catenin pathway rationalizes innovative strategies for personalized cancer treatment. Further investigations are warranted to confirm precise and secure targeted agents and achieve optimal use with clinical benefits in malignant diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |